Study Objectives: Nucleosomes and cell-free double-stranded DNA (dsDNA) have been suggested as promising biomarkers in cell death-related diseases, such as acute coronary syndrome (ACS). Currently, the impact of obstructive sleep apnea (OSA) in patients with ACS is unclear. Our aim was to evaluate the relationship between OSA, dsDNA, and nucleosomes and to assess their potential implication in the development of ACS. Methods: Up to 549 patients were included in the study and divided into four groups (145 ACS; 290 ACS + OSA; 62 OSA; 52 controls). All patients underwent a sleep study, and serum concentrations of dsDNA and nucleosomes were measured. Results: Nucleosome and dsDNA levels were higher in patients with OSA than in controls (nucleosomes: 1.47 ± 0.88 arbitary units [AU] vs. 1.00 ± 0.33 AU; p < .001, dsDNA: 315.6 ± 78.0 ng/mL vs. 282.6 ± 55.4 ng/mL; p = .007). In addition, both biomarker levels were higher in patients with ACS than in non-ACS, independently of the presence of OSA. Conclusions: Both nucleosomes and dsDNA are increased in patients with OSA and might be related with the high cardiovascular risk seen in these patients. The extensive cell lysis during a myocardial infarction seems to be the major contributor to the high biomarker levels, and OSA does not seem to be implicated in such elevation when this acute event occurs. Clinical trial registration: NCT01335087 (clinicaltrials.gov)
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INTRODUCTION
Obstructive sleep apnea (OSA) syndrome is a multifactorial medical condition where the upper airway dimensions are reduced as a result of both anatomical and functional alterations. 1, 2 During an apnea event (complete airway collapse) or a hypopnea (partial collapse), the airway is narrowed and oxygen saturation is reduced. The intermittent hypoxia could play an essential role in OSA pathophysiological consequences and comorbidities, such as an increased risk of cardiovascular disease and death of any cause. 3, 4 Although OSA has been suggested as an independent risk factor for cardiovascular events, the molecular mechanisms underlying such relationship are not clear to date. 5, 6 During cell death, intracellular components are leaked into the bloodstream. Therefore, a myriad of biochemical markers is currently detected and quantified in blood for the assessment of human pathologies. Among them, troponin I and troponin T are currently the most specific biomarkers for the diagnosis and follow-up of an acute myocardial infarction (MI).
Particularly during apoptosis, endonucleases are activated and specifically cleave easily accessible sites of chromatin into multiple mononucleosomes and oligonucleosomes. 7 Nucleosomes are the building blocks of chromatin and consist of octamers of basic proteins (histones) surrounded by double-stranded DNA (dsDNA). When apoptosis, necrosis, or other kinds of cellular senescence occur, both nucleosomes and protein-free DNA are leaked into the circulation. 8 In physiological conditions, nucleosomes released into the bloodstream are quickly and effectively removed. 9, 10 Therefore, only little amounts can be detected in the serum of a healthy individual. When cell death phenomena are increased, such as in patients with cardiovascular disease, inflammation or cancer, high concentrations of mononucleosomes/oligonucleosomes and cell-free dsDNA may be found. [11] [12] [13] [14] As a result, both may be useful serum biomarkers for the detection of tissue injury, although nonspecific, and might correlate with the extension of the damage. 15, 16 Emerging bibliography is being published regarding the usefulness of nucleosomes and cell-free DNA in necrosis-related
Statement of Significance
Serum nucleosomes and double-stranded DNA are cell components that may be leaked into the bloodstream during cell death. We found increased blood concentrations of both components in patients with obstructive sleep apnea (OSA) and even higher in patients with myocardial infarction. We suggest that both biomarkers might be related with the high cardiovascular risk seen in patients with OSA. When a myocardial infarction occurs, the extensive cell death in such event is the major contributor to the high levels seen in these patients. Therefore, OSA does not seem to be implicated in cellfree nucleosome or double-stranded DNA elevation after a myocardial infarction.
diseases, such as coronary diseases and cancer, 13, 17 two of the leading causes of morbidity and mortality in the Western societies. Both biomarkers may be regarded as two independent risk factors for atherosclerosis and cardiovascular disease. For instance, dsDNA was suggested to play a role in the pathogenesis of MI 18 and to be a determinant of a prothrombotic state. 19 In fact, it was shown to be more sensitive and peak earlier than cardiac troponin I, 13 and its concentrations increase proportionately to the complications arising from an acute coronary syndrome (ACS). 16, 20 Our hypothesis was that OSA generates an increased cardiovascular risk, which translates into increased levels of circulating cell death biomarkers, among others. When an MI takes place, the extensive cell lysis would induce remarkably higher concentrations of nucleosomes and dsDNA in blood than those seen in patients with OSA only. The aims of this study were (1) to assess the interrelationships between OSA and cell deathrelated biomarkers and (2) to evaluate their potential implication in the development and evolution of an ACS. To this end, serum nucleosomes and dsDNA were measured in four groups: individuals with no previous cardiovascular event (with and without OSA) and patients with ACS (with and without OSA).
MATERIALS AND METHODS

Rationale and Study Design
This study was performed in two branches and included samples from individuals of two different sources: the Sleep Unit of Hospital Universitari Son Espases and the Impact of Sleep Apnea Syndrome in the Evolution of Acute Coronary Syndrome (ISAACC) Study (Figure 1 ).
In the first part of the study, individuals were recruited only from Hospital Universitari Son Espases and classified either as controls or OSA based on a sleep study. They had all referred to the sleep laboratory for snoring or suspected OSA, and none of them had any history of cardiovascular events.
As statistical differences in cell death biomarkers were seen, an expansion of the study was suggested. Therefore, patients from the ISAACC trial were also included independently and in parallel, before starting continuous positive airway pressure (CPAP) treatment. The ISAACC Study (registered as NCT01335087 on clinicaltrials.gov) is a multicenter, parallel, prospective, randomized control trial that started in April 2011. 21 Therefore, samples from patients recruited since 2011 (and stored at −80ºC) were analyzed after obtaining the results of the initial cohort. The ISAACC trial is evaluating the effects of CPAP treatment on the incidence of new cardiovascular events in patients with an episode of ACS and OSA. These later included patients were from several hospitals in Spain and classified into two groups: either ACS or ACS + OSA.
Participants and Procedures
All patients included in the study provided written, informed consent, and the present it was approved by the Ethics Board of our hospital.
For the initial study, participants underwent a polysomnography (Grael, Compumedics, Australia), and OSA classification was carried out using the apnea-hypopnea index (AHI). Oronasal flow, thoracoabdominal movements, electrocardiogram, and pulse oximetry were recorded. Apnea is defined as an absence of airflow lasting ≥10 seconds. Hypopnea is defined as a discernible reduction (between 30% and 90%) in the width of the respiratory signal lasting more than 10 seconds or an evident reduction in the thoracoabdominal result accompanied by oxygen desaturation (≥3%) and/or a microarousal on the electroencephalogram. AHI represents the number of apneas and hypopneas per hour of sleep and was calculated manually by attending physicians. An AHI threshold of 10 h −1 was established for the diagnosis of OSA, according to daily clinical practice. The control group was defined by the absence of OSA. The exclusion criteria for this initial study were the following: previous CPAP treatment; psychophysical inability to complete questionnaires; the presence of any previously diagnosed sleep disorder; more than 50% of apneas consisting of central apneas or the presence of Cheyne-Stokes respiration; the presence of daytime sleepiness (Epworth Sleep Scale score > 10); the presence of chronic diseases, including neoplasms, renal insufficiency (glomerular filtration rate < 15 mL/ min/1.73 m 2 ), severe chronic obstructive pulmonary disease (forced expiratory volume < 50%), chronic depression, and other limiting chronic diseases; a medical history that could interfere with the objectives of the study; and any processes, whether cardiovascular or otherwise, that reduced life expectancy to less than 1 year; and patients in cardiogenic shock.
To avoid possible biases based on the cutoff value selection, further analyses were also performed classifying participants into four different groups, depending on AHI: AHI <5 h For the second study (ISAACC branch), a polygraphic sleep test (Embletta, ResMed, Australia) was performed to every participant, and the diagnosis of OSA was based on the guidelines of the Spanish national consensus on apnea-hypopnea syndrome, 22 thus enabling the classification of individuals as either ACS or ACS + OSA (Figure 1 , right). According to the previously published ISAACC guidelines, 21 an AHI threshold of 15 per hour was used for the diagnosis of OSA in this branch. Upon hospital admission, echocardiographic evaluations and Killip classifications were also routinely performed.
Biochemical Analysis
Peripheral blood samples were collected from all participants in the morning after the sleep study, in order to minimize possible diurnal patterning of biomarker release. Serum samples were stored at −80ºC until analysis. Blood chemistry analyses (glucose, creatinine, total cholesterol, and high-density lipoprotein [HDL] cholesterol) were performed using commercially available assays (Architect c16000 platform, Abbott Diagnostics). Nucleosome levels were analyzed in serum using the Cell Death Detection ELISA Plus kit (Roche Diagnostics), and results were quantified using the enrichment factor (by comparison with negative pooled sera). The mean of the control group (non-ACS/non-OSA) was normalized to 1 and expressed in arbitrary units (AU). Levels of dsDNA were quantified in duplicate in serum using the Quant-iT TM Picogreen ® dsDNA kit (Invitrogen), following manufacturer's instructions. Coefficients of variation were 9% for nucleosomes (in-house checked, data not shown) and 2.7% for dsDNA (stated by manufacturer).
Data Analysis
All data (demographical, polygraphic, and biochemical) were included in a database. The mean values (standard deviations) or frequencies (and percentages) were compared between the control group and the OSA group (initial study) and between the two ACS groups (with and without OSA). Differences were evaluated using Mann-Whitney tests (or Student t tests, if normally distributed), or chi-squared tests. When patients were classified into more than two groups, analyses of variance were performed. The associations between nucleosomes, dsDNA, and other variables were assessed using a linear regression models, as appropriate. Additionally, the models were adjusted for age, gender, body mass index (BMI), HDL cholesterol, systolic blood pressure, smoking status, and glucose levels.
The SPSS v19 software (IBM Corporation, New York) was used for all statistical analyses, and significance was set at 0.05.
RESULTS
A total of 549 individuals were finally included and divided into: participants with no previous cardiovascular event (52 with OSA and 62 without OSA) and participants with ACS (290 with OSA and 145 without OSA). The clinical characteristics of the participants are outlined in Table 1 (initial study) and Table 2 (second study). In the non-ACS group, patients with OSA were significantly older, had higher BMI, higher glucose levels and systolic blood pressure, and smoking was more prevalent.
Nucleosome levels were higher in patients with OSA compared with controls (1.47 ± 0.88 AU vs. 1.00 ± 0.33 AU; p < .001). Such nucleosome levels correlated positively with AHI (r = +0.562, p < .001), BMI (r = +0.360, p < .001), and glucose levels (r = +0.217, p = .026) and negatively with both mean and minimum oxygen saturation (r = −0.396, p < .001 and r = −0.438, p < .001, respectively). No significant correlation was obtained between nucleosome levels and age, total cholesterol, HDL cholesterol, and blood pressure. In a linear regression analysis, after adjusting for potential confounding variables (age, gender, BMI, HDL cholesterol, systolic blood pressure, and glycemia), nucleosome levels were associated with AHI (p < .001), whereas no association with any other assessed variable was detected (BMI, glucose, cholesterol, blood pressure) (Figure 2A) . dsDNA levels were also higher in patients with OSA compared with controls (315.6 ± 78.0 vs. 282.6 ± 55.4 ng/mL; p = .007). dsDNA concentration also correlated with AHI (r = +0.267, p = .004), although the strength of correlation was lower than for nucleosomes. Also with age (r = +0.303, p = .001), total cholesterol (r = +0.270, p = .005), HDL cholesterol (r = +0.287, p = .003), and systolic blood pressure (r = +0.282, p = .003). No correlation was seen with other variables such as glucose levels, mean or minimum oxygen saturation (p = .157 and p = .125, respectively), or BMI (p = .317). Moreover, after adjusting for age, gender, BMI, HDL cholesterol, glucose levels, smoking status, and blood pressure (even some of them not significant in single variate analyses), either dsDNA and nucleosome levels still significantly correlated with AHI (p = .049 and p < .001, respectively) ( Table 3) . Of all variables included in the analysis, AHI is the one that most explains both nucleosome and dsDNA concentration variation (Table 3) .
When considering the whole non-ACS cohort and dividing participants into four groups based on AHI (<5 h −1 ; 5-10 h −1 ;
10-15 h −1 , and >15 h −1 ), statistical significance remained among groups (p < .001 for nucleosomes; p = .017 for dsDNA), thus suggesting that the AHI cutoff value selection has no impact on our findings (Figure 3 ).
In patients with ACS (Table 2) , OSA was detected in 67% of cases. The patients with OSA were older and with higher BMIs. No differences in OSA prevalence were detected between genders. Nucleosome and dsDNA levels were increased compared with non-ACS patients (for nucleosomes: 3.46 ± 4.33 AU vs. 1.14 ± 0.37 AU; p < .001 and for dsDNA: 556.9 ± 167.8 ng/mL vs. 297.9 ± 55.2 ng/mL; p < .001). However, no differences were obtained between patients with and without OSA (for nucleosomes: 3.81 ± 1.44 AU vs. 3.23 ± 2.02 AU; p = .101 and for dsDNA: 539.6 ± 146.4 ng/ mL vs. 565.9 ± 177.5 ng/mL; p = .120), either adjusting for age and BMI or not (Figure 2 ). Differences in this cohort were neither seen when individuals were classified in four AHI groups (<5 h −1 ; 5-10 h −1 ; 10-15 h −1 , and >15 h −1 ): p = .324 for nucleosome concentration and p = .132 for dsDNA. 
DISCUSSION
The results of our study show that nucleosomes and dsDNA in serum are increased in patients with OSA in comparison with participants without OSA. An increase in both cell death biomarkers was also detected in ACS patients compared with patients without any cardiovascular event, independently of the presence of OSA. The present findings suggest that: (1) OSA may be implicated in the increased levels of the two cell deathrelated biomarkers; (2) the extensive cell lysis resulting from an MI appears to be the major contributor to the high levels of both biomarkers detected in patients after an ACS; (3) OSA does not seem to contribute to such elevation when this acute event occurs.
OSA and Cell Death Biomarkers
Although OSA-independent elevations were detected in patients with ACS, significant increases were seen for dsDNA and nucleosomes in OSA patients without coronary disease. Despite using different quantification methods and sample types, our findings are consistent with a previous case-control study by Shin et al., 23 where high cell-free DNA concentrations correlated with a higher OSA prevalence in patients without coronary disease. The previous publication reported an association between AHI and dsDNA concentration on a multivariate analysis, and we further confirmed such relationship by performing a linear correlation analysis and showing a positive and significant association between AHI and both nucleosomes and dsDNA.
Nucleosomes and ACS
To our knowledge, only one study has previously assessed the serum concentration of nucleosomes in patients with MI. 19 In this report, nucleosome high baseline studies were described to show an odds ratio of 2.59 for the prediction of major adverse cardiac events. This observation further supports our hypothesis that extensive cell death occurs after a cardiovascular event. Intracellular components appear to be massively leaked in the bloodstream in ACS patients, whereas neither liver metabolization nor immune-mediated clearance can effectively remove them. However, because several other critical conditions have also shown to increase cell-free DNA levels, such as infection, cancer, and respiratory insufficiency, 24 the release of such biomarkers might result from an inflammatory state, 25 which is greatly increased in MI. In our study, in spite of different recruitment and AHI thresholds, an almost fourfold increase in nucleosome levels was detected after an ACS for patients without OSA. In addition, a twofold increase was seen after a cardiovascular event for patients with OSA. These results are concordant with the twofold increase seen in patients with deep vein thrombosis, 12 the 2.4-fold increase in patients with severe coronary atherosclerosis 19 and the 2.56-fold increase in patients with heart failure. 26 By contrast, observations published elsewhere described a cardioprotective role for OSA in the acute phase of a myocardial ischemic injury. 27, 28 Shah et al. found lower blood troponin T levels after an MI in individuals with more severe OSA compared with those without OSA, thus suggesting a possible adaptation situation in patients with sleep apnea. In this sense, further studies are needed to clarify the possible ischemic preconditioning behavior of OSA and its scope after a nonfatal cardiac event.
Serum dsDNA and MI
Although alternative dsDNA quantification methods were used in literature, our observations in patients with ACS are consistent with previous studies assessing free DNA concentrations in serum or plasma samples. Using a bDNA-based Alu assay, two different studies obtained a 45-fold increase 23 and a 19-fold increase 16 in MI patients, respectively, whereas another quantitative polymerase chain reaction study yielded a twofold increase of nuclear DNA concentrations in ACS patients on hospital day 1 compared to a non-MI control group. 20 A study performed using our same methodology stated that patients after ACS had a 10-fold increase in cell-free DNA compared to healthy controls. 17 Compared to our results, where a twofold increase was observed in ACS patients compared to the control group, the differences in the degree of the increase (10-fold vs. 2-fold) are most probably due to the selection of the control group, as the dsDNA values in the ACS groups are similar between studies (510.6 ± 398.0 ng/mL in Chang et al. 17 vs. 556.9 ± 167.8 ng/ mL in our study). The gradual increase in dsDNA concentrations, as well as in nucleosomes, further corroborates the abovementioned hypothesis and underlines OSA as an independent contributor to the high biomarker levels, possibly related with the high cardiovascular risk seen in patients with OSA. Nevertheless, the high concentrations of both biomarkers seen after an ACS could derive from an extensive cell lysis resulting from an MI, regardless of the presence of OSA. These observations were independent of the AHI cutoff value election.
The results of the present study also contribute to the possibility that OSA might be a risk determinant for atherosclerosis and help in the understanding of the pathophysiological mechanisms of ACS. Well-established relationships between cell death biomarkers and vascular diseases have already been published elsewhere, including dsDNA elevations in acute ischemic stroke. 29 However, a recent trial including patients with a history of coronary artery disease or cardiovascular disease and OSA showed that the use of CPAP would not reduce the rate of MI, stroke, heart failure, or death from cardiovascular causes. 3 Nevertheless, the link between sleep-breathing disorders and cardiovascular disease might be further elucidated as the ISAACC trial moves forward.
Multiple hypotheses link increased extracellular DNA concentrations with the initiation or exacerbation of atherosclerosis, acting as a link between innate and adaptive immune responses. 29 Our results suggest that these mechanisms might be exacerbated and play an important role in the high cardiovascular risk observed in patients with OSA. Moreover, circulating dsDNA, nucleosomes, and even myeloperoxidase-DNA complexes have been reported to be associated an increased cardiovascular risk. 19, 30, 31 Although their role in the pathogenesis is still unclear, 32, 33 all three biomarkers were suggested as independent determinants of a prothrombotic state, as robust correlations were obtained with well-established prothrombotic biomarkers, such as thrombin-antithrombin complexes and von Willebrand factor levels. 34 This study has several limitations. First, during patient recruitment, those with daytime sleepiness were excluded from the study, which were the patients with most severe OSA. Moreover, in ACS patients, OSA was diagnosed based on a respiratory polygraphy, which is claimed to sometimes underestimate the severity of the disease. Second, a higher number of controls would have raised the power of the observations. Third, the analytical conditions of the measurements: the high variability of serum nucleosome quantification may limit its usefulness as biomarker and hamper the conclusions drawn thereof, as well as the lack of robust information regarding the dependence of dsDNA or nucleosomes with other preanalytical variables, such as age, gender, ongoing medications, diabetes, or dyslipidemia. In addition, the intrascorer and interscorer variation could add some variability in the interpretation of the sleep studies. Furthermore, additional studies assessing shortand long-term issues are yet to be performed for a better evaluation of the role of cell death in the whole pathophysiological process.
CONCLUSIONS
Differential nucleosome and dsDNA levels among controls, patients with OSA without cardiovascular disease and patient with ACS bring to light potential implications of these cell death biomarkers in the pathological mechanisms of atherosclerosis and the development of coronary events. Our observations reveal that the two cell death-related biomarkers may play an important role in the high cardiovascular risk seen in patients with OSA. The high levels of both biomarkers detected in patients after an ACS could derive from an extensive cell death resulting from an MI, independently of the presence of OSA.
Additional studies evaluating cardiovascular event outcomes are warranted, for a better assessment of the actual impact of nucleosomes and dsDNA in the cardiovascular disease and the underlying molecular mechanisms.
